Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
IMMX
IMMX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
IMMX News
Immix Biopharma Initiated with Overweight Rating by Morgan Stanley
10h ago
seekingalpha
Latest Rating Changes on Wall Street
14h ago
CNBC
Wall Street Analysts Adjust Ratings
Mar 09 2026
Benzinga
Wall Street Analysts Adjust Ratings
Mar 09 2026
Benzinga
Wall Street Analysts Adjust Ratings on Key Stocks
Mar 09 2026
Benzinga
NXC-201 Receives FDA Breakthrough Therapy Designation
Jan 28 2026
Newsfilter
Healthcare Stocks Surge in After-Hours Trading
Jan 28 2026
NASDAQ.COM
Immix Biopharma Files $750 Million Shelf Registration for Stock Offerings
Jan 12 2026
Benzinga
ImmixBio Closes 19.1M Share Offering, Netting $93.7M
Dec 09 2025
Globenewswire
ImmixBio Closes 19.1M Share Offering, Netting $93.7M
Dec 09 2025
Newsfilter
Immix Rises Following NXC-201 Results in Relapsed/Refractory AL Amyloidosis; BLA Expected in 2026
Dec 08 2025
NASDAQ.COM
Immix Biopharma Announces $100M Equity Raise Through Common Stock and Warrant Offering
Dec 08 2025
SeekingAlpha
ImmixBio Prices 19.1M Shares at $5.10, Raising $100M
Dec 08 2025
Globenewswire
ImmixBio Prices 19.1M Shares at $5.10, Raising $100M for NXC-201 Development
Dec 08 2025
Newsfilter
ImmixBio's NXC-201 Achieves 75% Complete Response Rate in Phase 2 Trials
Dec 08 2025
Newsfilter
Immix Biopharma's NXC-201 Phase 2 Trial Shows 75% Complete Response Rate
Dec 07 2025
Globenewswire
Show More News
